Dolutegravir as maintenance monotherapy: first experiences in HIV-1 patients: Table 1.
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Dolutegravir as maintenance monotherapy: first experiences in HIV-1 patients: Table 1.
Authors
Keywords
-
Journal
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
Volume 71, Issue 6, Pages 1632-1636
Publisher
Oxford University Press (OUP)
Online
2016-02-19
DOI
10.1093/jac/dkw011
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Protease inhibitor monotherapy for long-term management of HIV infection: a randomised, controlled, open-label, non-inferiority trial
- (2015) Nicholas I Paton et al. Lancet HIV
- Simplification to atazanavir/ritonavir monotherapy for HIV-1 treated individuals on virological suppression
- (2014) Antonella Castagna et al. AIDS
- Dolutegravir versus placebo in subjects harbouring HIV-1 with integrase inhibitor resistance associated substitutions: 48-week results from VIKING-4, a randomized study
- (2014) Bisher Akil et al. ANTIVIRAL THERAPY
- Antiretroviral Treatment of Adult HIV Infection
- (2014) Huldrych F. Günthard et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Pharmacokinetics of dolutegravir when administered with mineral supplements in healthy adult subjects
- (2014) Ivy Song et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study
- (2014) A. Castagna et al. JOURNAL OF INFECTIOUS DISEASES
- Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study
- (2014) Bonaventura Clotet et al. LANCET
- The PROTEA trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV-1 RNA below 50 copies/mL
- (2014) Andrea Antinori et al. Journal of the International AIDS Society
- Dolutegravir in antiretroviral-naive adults with HIV-1
- (2013) Hans-Jürgen Stellbrink et al. AIDS
- Economic Savings Versus Health Losses: The Cost-Effectiveness of Generic Antiretroviral Therapy in the United States
- (2013) Rochelle P. Walensky et al. ANNALS OF INTERNAL MEDICINE
- Pharmacokinetics of dolutegravir in HIV-seronegative subjects with severe renal impairment
- (2013) Stephen Weller et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study
- (2013) Pedro Cahn et al. LANCET
- Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial
- (2013) François Raffi et al. LANCET INFECTIOUS DISEASES
- Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection
- (2013) Sharon L. Walmsley et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dolutegravir Interactions with HIV-1 Integrase-DNA: Structural Rationale for Drug Resistance and Dissociation Kinetics
- (2013) Felix DeAnda et al. PLoS One
- Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study
- (2012) Joseph J. Eron et al. JOURNAL OF INFECTIOUS DISEASES
- Dolutegravir (S/GSK1349572) Exhibits Significantly Slower Dissociation than Raltegravir and Elvitegravir from Wild-Type and Integrase Inhibitor-Resistant HIV-1 Integrase-DNA Complexes
- (2011) Kendra E. Hightower et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In VitroAntiretroviral Properties of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor
- (2010) Masanori Kobayashi et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV
- (2009) Federico Pulido et al. AIDS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started